高级别胶质瘤的免疫治疗与靶向治疗:现状与未来方向
本文综述高级别胶质瘤靶向治疗与免疫治疗的临床开发进展。文章汇总了IDH、VEGF、RTK信号、MGMT、PARP等分子靶点,以及免疫检查点抑制、CAR-T、TCR、TIL、疫苗、溶瘤病毒等策略。作者认为高级别胶质瘤是涉及分子通路、微环境与神经调控相互作用的网络性疾病,新兴疗法多机制并行为未来治疗带来希望。
要点
- 高级别胶质瘤预后普遍较差,治疗选择有限
- 分子靶点涵盖IDH、VEGF、RTK信号、MGMT、PARP、TERT、ATRX等
- 免疫策略包括检查点抑制、细胞治疗、疫苗、溶瘤病毒及癌症神经科学疗法
核心结论
- 高级别胶质瘤是涉及肿瘤内在通路、抗原性、免疫识别与攻击及神经元调控的相互连接的网络性疾病。
- 新兴疗法常同时利用多个交叉机制,为这类难治性肿瘤的未来临床治疗带来希望。
研究设计与样本
- 本文为综述,聚焦高级别胶质瘤分子靶向治疗与免疫治疗在近期及进行中临床试验中的临床开发。
- 文章回顾相关临床开发工作,讨论持续存在的挑战,并强调靶向干预的新兴机会。
主要发现
- 文中讨论的分子靶点包括IDH、VEGF、RTK信号(EGFR、PI3K/Akt、Ras/Raf/MEK)、p53、CDKN2A/B、CDK4/6、MGMT、PARP、TERT和ATRX。
- 免疫治疗策略包括免疫检查点抑制(含经典与新兴靶点)、细胞免疫治疗(CAR-T细胞、TCR治疗、TIL治疗及其他工程化细胞治疗)、癌症疫苗和溶瘤病毒。
- 文章还提及基于癌症神经科学的新兴机制治疗。
临床怎么用
- 文中未给出可直接用于临床决策的阈值、剂量或推荐等级。
局限性
- 本文为综述,未报告具体研究设计细节与量化结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High grade gliomas are aggressive intrinsic brain tumors with limited treatment options and a universally poor prognosis. In recent years, significant progress has been made in understanding the genetic and molecular underpinnings of high grade gliomas and their interactions with the tumor microenvironment, including vasculature, immune cells, neurons, and glia, and, consequently, in the development of novel molecularly targeted therapies and immunotherapies. METHODS: Here, we review ongoing work in the clinical development of new therapeutic strategies for high grade gliomas, discuss ongoing challenges, and highlight emerging opportunities for targeted intervention, with particular focus on molecularly targeted and immunotherapy in recent and ongoing clinical trials. RESULTS: We discuss relevant molecular targets in high grade glioma, including IDH, VEGF, RTK signaling (EGFR, PI3K/Akt, Ras/Raf/MEK), p53, CDKN2A/B, CDK4/6, MGMT, PARP, TERT, and ATRX, as well as contemporary immunotherapeutic strategies including immune checkpoint inhibition (including classical and emerging targets), cell-based immunotherapy (CAR-T cells, TCR therapy, TIL therapy, and other engineered cell therapies), cancer vaccines, oncolytic viruses, as well as emerging mechanisms including cancer neuroscience-based therapies. CONCLUSIONS: High grade glioma is a networked disease, involving numerous interconnected molecular and microenvironmental phenomena from tumor-intrinsic pathways and antigenicity to immune recognition and attack to neuronal modulation of both tumor and immune signaling. Emerging therapies harness several of these intersectional mechanisms, often simultaneously, and together offer hope for the future of clinical treatment of these devastating cancers. Not applicable.
引用
- Hsueh B, Steuart SJ, Odukoya AO, et al. Immunotherapy and targeted therapy for high grade gliomas: current and future directions. J Neurooncol. 2025. PMID: 41366148. doi:10.1007/s11060-025-05315-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。